Direct Factor Xa Inhibitor

7 Drugs classified under this drug class

Anticoagulant, Direct Factor Xa Inhibitor. Apixaban 2.5 mg, Apixaban 5 mg.
FC tabs 2.5mg/5 mg X30
Prevent. of VTE (VTEp): elect. hip or knee replacem. surgery 2.5 mg taken orally 2Xd, initial dose to be taken 12 to 24 hs after surg. In ptts. undergoing hip replacem., tmt. is 32 to 38 days. In ptts. undergoing knee replacem., tmt. is 10 to 14 days. Prevent. of stroke and syst. embol. in ptts. with non-valv. atrial fibrill. (NVAF): 5 mg taken orally 2Xd. See full prescript. info.
 for 2.5 mg: prevent. of venous thromboemb. events (VTE) in adlt. ptts. who have undergone elect. hip or knee replacem.
 for both 2.5 and 5 mg: prevent. of stroke and syst. embol. in adlt. ptts. with non-valv. atrial fibrill. (NVAF), with one or more risk factors, such as prior stroke or transient isch. attack (TIA); age≥ 75 y; HT; diabetes mellitus; sympt. heart fail. (NYHA Class ≥ II). Tmt. of deep vein thromb.(DVT) and pulmon. embol. (PE), and prevent. of recurrent DVT and PE in adults.
C/I: Hypersens. Act. clin. signif. bleeding. • Hep. dis. assoc. with coagulopathy and clinic. relevant bleeding risk • Lesion or condit. posing a signif. risk factor for major bleeding, incl. current or recent GI ulcerat., presence of malign. neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surg., recent intracran. haemorrhage, known or susp. oesophageal varices, arteriovenous malform., vasc. aneurysms or major intraspinal or intracerebral vasc. abnorm. • Concom. tmt. with any other anticoag. agent e.g. unfraction. heparin (UFH), low MW heparins (enoxaparin, dalteparin, etc.), heparin deriv. (fondaparinux, etc.), oral anticoag. (warfarin, rivaroxaban, dabigatran, etc.) except under spec. circumst. of switching anticoag. ther. or when UFH is given at doses necess. to maintain an open ctral. venous or arterial catheter.

Anticoagulant, Direct Factor Xa Inhibitor. Apixaban 2.5 mg, 5 mg.
Preven. of VTE (VTEp): elective hip or
knee replac. surg.- 2.5 mg ×2/d.
Init. dose should be taken 12 - 24 hrs.
after surg.
In pts. underg. hip replac. surg.- The
recom. duration of tmt. is 32- 38 d.
In pts. underg. knee replac. surg.: The
recom. duration of tmt. is 10- 14 d.
Preven. of stroke & syst. embol. in pts.
with non-valvul. atrial fibril. (NVAF):
5 mg ×2/d.
Dose reduction: 2.5mg×2/d in pts. with
NVAF and at least two of the follow.
characteristics: age ≥ 80 yrs., bdy. wt. ≤
60 kg, or ser. Cr ≥ 1.5 mg/dL (133
micromole/L).
Ther. should be cont. long term.
Tmt. of DVT, tmt. of PE and preven. of
recur. DVT &PE (VTEt)
Tmt. of acute DVT and tmt. of PE is 10
mg×2/d for the first 7 d. follow. by 5
mg ×2/d.
As per avail. med. guidelines, short
durat. of tmt. (at least 3 mnths.) should
be based on transient risk factor. (e.g.
recent surg., trauma, immobilis.).
Preven. of recur. DVT & PE is 2.5
mg×2/d. When preven. of recur. DVT &
PE is indic., the 2.5 mg×2/d should be
init. follow. complet. of 6 mnths. of tmt.
5 mg×2/d or with another anticoag.
See Lit.
2.5 mg tabs. - Preven. of VTE in adult pts.
who have undergone elect. hip or knee
replac. surg.
Preven. of stroke and syst. embol. in adult
pts. NVAF, with one/ more risk fact., e.g as
prior stroke, TIA; age ≥ 75 yrs.; hypertens.;
diabetes. mell.; symptom. HF (NYHA Class
≥ II).
Tmt. of DVT, PE , and preven. of recur.
DVT & PE in adult.
5 mg tabs. - Preven. of stroke, syst. embol.
in adult pts. NVAF, with one/ more risk
fact., e.g. prior stroke or TIA; age ≥ 75 yrs.;
hypertens.; diabetes mell.; symptom. HF
(NYHA Class ≥ II).
Tmt. of DVT, PE in adult. 
C/I: Hypersens.
Active clinic. signific. bleed.
Hep. dis. assoc. with coagulopathy
&clinic. relevant bleed. risk.
Lesion/ condit. if consid. a signific. risk
factor for major bleed. This may include
current or recent GI ulcer., presence of
malig. neoplasm. at high risk of bleed.,
recent brain, spinal inj., recent brain,
spinal or ophthalmic surg., recent
intracran. haemorrhage, known/
suspect. esophagi. varices, arterioven.
malform., vasc. aneurysms or major
intraspinal or intracerebr. vascular
abnorm.
Concom. tmt. with any other anticoag.
agent e.g. unfraction. heparin (UHF), low
molec. wt. heparins (enoxaparin,
dalteparin, etc.), heparin derivat.
(fondaparinux, etc.), oral anticoag.
(warfarin, rivaroxaban, dabigatran, etc.)
except under specific circumstances of
switching anticoag. ther.or when UHF is
given at doses necessary to maintain an
open centr. ven. or arterial catheter or when UFH is given during catheter ablation for atrial fibrillation

Antithrombotic Agent, Direct Factor Xa Inhibitor. Edoxaban 15 mg , 30 mg , 60 mg.
FC tab.: 10/28/30X15/30/60 mg.edoxaban
Prevent. of stroke and syst. embol. in adlt pts with nonvalv. atrial fibrill (NVAF) with risk factors, such as congest. HF, HyperT, age ≥ 75 years, diab. mell., prior stroke or trans. isch. attack (TIA).
Tmt of deep vein thromb. (DVT) and pulm. embol. (PE), and
prevent. of recurr. DVT and PE in adults
C/I: Hypersens.
Clinic. sign. act. bleeding.
Hepatic dis. assoc. with coagulopathy and clin. relev. bleeding risk.
Lesion or condit., with a sign. risk for major bleed. such as curr. or recent GI ulcerat., malign. neopl. at high risk of bleed., recent brain or spinal inj., recent brain, spinal or ophth. surg., recent intracranial haemorrh., known or susp. oesophageal varices, arteriovenous malform., vasc. aneurysms or major intraspinal or intracerebr. vasc. abnorm.
Uncontroll. sev. hypert.
Concom. tmt with other anticoag. e.g. UFH, LMWH (enoxaparin, dalteparin, etc.), heparin deriv. (fondaparinux, etc.), oral anticoag. (warfarin, dabigatran etexilate, rivaroxaban, apixaban etc.) except under spec. circumst. of switching oral anticoag. ther. or when UFH is given at doses to maintain an open ctral ven. or arter. catheter.
Pregn. and breast-feed.

Pregn. and breast-feed.

Direct Factor Xa Inhibitor. Rivaroxaban 2.5 mg, 10 mg, 15 mg, 20 mg.
FCTabs  56 X 2.5 mg, 30 X 10 mg, 28 X 15 mg, 328 X 20 mg
Dosage to be adjusted indiv. according to the ptt.’s medic. condit. See lit.
Rivaroxaban 2.5 mg:
co-admin. with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel, for the prevent. of atherothrombotic events in adults after an ac. coron. syndr. (ACS) with elevated card. biomarkers.
co-admin. with acetylsalicylic acid (ASA), for the prevent. of atherothrombotic events in adults with coronary artery dis. (CAD) or symptom. peripheral artery dis. (PAD) at high risk of ischaemic events.
Rivaroxaban 10 mg:
Prevent. of venous thromboembolism (VTE) in adults undergoing elective hip or knee replacement surgery.
Prevent. of recurrent deep vein thrombosis (DVT) and pulm. embolism (PE), in adults (following completion of at least 6 months ther. for DVT or PE).
Rivaroxaban 15 mg and 20 mg:
Prevent. of stroke and syst. embolism in adults with non-valvular atrial fibrillation with one or more risk factors, such as congestive HF, HT, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack.
Tmt. of deep vein thrombosis (DVT), and pulm. embolism (PE), and prevent. of recurrent DVT and PE in adults
Paediatric pop.: Tmt. of venous thromboembolism (VTE) and prevent. of VTE recurrence in childr. and adolesc. aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoag. tmt.
C/I for 2.5, 10, 15 and 20 mg prod.:
 Hypersens./Active clin. signif.bleeding/
Lesion or condit. posing significant risk for major bleeding.: GI ulcer., neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, oesophageal varices, arteriovenous malformat./ vasc. aneurysms or major intraspinal or intracerebral vasc. abnormalities/
Concom. tmt. with any other anticoag. e.g. unfractionated heparin (UFH), low molec. weight heparins (enoxaparin, dalteparin, etc.), heparin derivat. (fondaparinux, etc.), oral anticoag. (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumst. of switching anticoag. ther. or when UFH is given at doses necessary to maintain an open ctral. venous or arterial catheter/ Hepatic dis. associated with coagulopathy and clinic. relevant bleeding risk includ. cirrhotic pts. with Child Pugh B and C/ Pregn. and breast feeding.
For 2.5 mg prod.: Concom. tmt. of ACS with antiplatelet ther. in pts with a prior stroke or a transient ischaemic attack (TIA).
* Concom. tmtt of CAD/PAD with ASA in pts with previous haemorrhagic or lacunar stroke, or any stroke within a month

Direct Factor Xa Inhibitor. Rivaroxaban 2.5, 10, 15, 20 mg.
FCTabs  60 X 2.5 mg, 30 X 10 mg, 30 X 15 mg, 30 X 20 mg
Dosage to be adjusted indiv. according to the ptt.’s medic. condit. See lit.
Rivaroxaban 2.5 mg:
co-admin. with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel, for the prevent. of atherothrombotic events in adults after an ac. coron. syndr. (ACS) with elevated card. biomarkers.
co-admin. with acetylsalicylic acid (ASA), for the prevent. of atherothrombotic events in adults with coronary artery dis. (CAD) or symptom. peripheral artery dis. (PAD) at high risk of ischaemic events.
Rivaroxaban 10 mg:
Prevent. of venous thromboembolism (VTE) in adults undergoing elective hip or knee replacement surgery.
Prevent. of recurrent deep vein thrombosis (DVT) and pulm. embolism (PE), in adults (following completion of at least 6 months ther. for DVT or PE).
Rivaroxaban 15 mg and 20 mg:
Prevent. of stroke and syst. embolism in adults with non-valvular atrial fibrillation with one or more risk factors, such as congestive HF, HT, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack.
Tmt. of deep vein thrombosis (DVT), and pulm. embolism (PE), and prevent. of recurrent DVT and PE in adults
C/I for 2.5, 10, 15 and 20 mg prod.:
  Hypersens./Active clin. signif.bleeding/
Lesion or condit. posing significant risk for major bleeding.: GI ulcer., neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, oesophageal varices, arteriovenous malformat./ vasc. aneurysms or major intraspinal or intracerebral vasc. abnormalities/
Concom. tmt. with any other anticoag. e.g. unfractionated heparin (UFH), low molec. weight heparins (enoxaparin, dalteparin, etc.), heparin derivat. (fondaparinux, etc.), oral anticoag. (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumst. of switching anticoag. ther. or when UFH is given at doses necessary to maintain an open ctral. venous or arterial catheter/ Hepatic dis. associated with coagulopathy and clinic. relevant bleeding risk includ. cirrhotic pts. with Child Pugh B and C/ Pregn. and breast feeding.
for 2.5 mg prod.: Concom. tmt. of ACS with antiplatelet ther. in pts with a prior stroke or a transient ischaemic attack (TIA).
* Concom. tmtt of CAD/PAD with ASA in pts with previous haemorrhagic or lacunar stroke, or any stroke within a month